Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

Blood

Volumn 122, Issue 7, 2013, Pages 1214-1221

  Ravandi, Farhad ^a   Jorgensen, Jeffrey L ^a   Thomas, Deborah A ^a   O'Brien, Susan ^a   Garris, Rebecca ^a   Faderl, Stefan ^a   Huang, Xuelin ^a   Wen, Sijin ^a   Burger, Jan A ^a   Ferrajoli, Alessandra ^a   Kebriaei, Partow ^a   Champlin, Richard E ^a   Estrov, Zeev ^a   Challagundla, Pramoda ^a   Wang, Sa A ^a   Luthra, Rajyalakshmi ^a   Cortes, Jorge E ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; ERYTHROCYTE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; CANCER STAGING; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; THIAZOLES; VINCRISTINE; YOUNG ADULT;

EID: 84887186227     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-466482     Document Type: Article

References (32)

1. Hoelzer D. Advances in the management of Ph-positive ALL. Clin Adv Hematol Oncol. 2006; 4(11): 804-805. (Pubitemid 44883546)
2. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009; 23(5): 1043-1063, vi.
3. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia. Blood. 2010; 116(12): 2070-2077.
4. Yanada M, Takeuchi J, Sugiura I., et al.; Japan Adult Leukemia Study Group. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006; 24(3): 460-466. (Pubitemid 46630465)
5. Thomas DA, Faderl S, Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103(12): 4396-4407. (Pubitemid 38745962)
6. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009; 27(31): 5175-5181.
7. Fielding AK, Rowe JM, Richards S.M., et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009; 113(19): 4489-4496.
8. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. In: ASH Education Book. Washington, DC: American Society of Hematology; 2011: 231-237.
9. Campana D. Minimal residual disease in acute lymphoblastic leukemia. In: ASH Education Book. Washington, DC: American Society of Hematology; 2010: 7-12.
10. Bassan R, Spinelli O, Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113(18): 4153-4162.
11. Gökbuget N., Kneba M, Raff T., et al.; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012; 120(9): 1868-1876.
12. Brüggemann M., Schrauder A, Raff T., et al.; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFM-SG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010; 24(3): 521-535.
13. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101(12): 2788-2801. (Pubitemid 39603187)
14. Weir EG, Cowan K, LeBeau P., Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia. 1999; 13(4): 558-567. (Pubitemid 29195284)
15. Luthra R, Sanchez-Vega B, Medeiros LJ. TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type. Mod Pathol. 2004; 17(1): 96-103. (Pubitemid 41656458)
16. Luthra R, Medeiros LJ. Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens. J Mol Diagn. 2004; 6(3): 236-242. (Pubitemid 39136652)
17. Szczepański T., Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002; 99(7): 2315-2323. (Pubitemid 34525415)
18. Schenk TM, Keyhani A, Bottcher S., et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia. 1998; 12(5): 666-674. (Pubitemid 28220818)
19. Cavé H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med. 1998; 339(9): 591-598.
20. Ratei R, Basso G, Dworzak M., et al.; AIEOP-BFM-FCM-MRD-Study Group. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia. 2009; 23(3): 528-534.
21. Dworzak MN, Fröschl G, Printz D., et al.; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002; 99(6): 1952-1958. (Pubitemid 34525474)
22. Nyvold C, Madsen HO, Ryder L.P., et al.; Nordic Society for Pediatric Hematology and Oncology. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002; 99(4): 1253-1258. (Pubitemid 34547078)
23. Vidriales MB, Pérez JJ, López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003; 101(12): 4695-4700. (Pubitemid 36857722)
24. Li A, Zhou J, Zuckerman D., et al. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood. 2003; 102(13): 4520-4526. (Pubitemid 37494119)
25. Raff T, Gökbuget N, Lüschen S, et al.; GMALL Study Group. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007; 109(3): 910-915. (Pubitemid 46220634)
26. Mortuza FY, Papaioannou M, Moreira I.M., et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20(4): 1094-1104. (Pubitemid 34141855)
27. Brüggemann M., Raff T, Flohr T., et al.; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006; 107(3): 1116-1123. (Pubitemid 43156313)
28. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010; 116(18): 3409-3417.
29. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118(25): 6521-6528.
30. Boulos N, Mulder HL, Calabrese C.R., et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 117(13): 3585-3595.
31. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1 ALL). In: ASH Education Book. Washington, DC: American Society of Hematology; 2009: 371-381.
32. Lee S, Kim YJ, Chung N.G., et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2009; 115(3): 561-570.